These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
735 related articles for article (PubMed ID: 9843178)
1. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator. Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178 [TBL] [Abstract][Full Text] [Related]
2. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor? Camani C; Gavin O; Kruithof EK Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388 [TBL] [Abstract][Full Text] [Related]
3. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis. Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782 [TBL] [Abstract][Full Text] [Related]
4. Pregnancy zone protein-tissue-type plasminogen activator complexes bind to low-density lipoprotein receptor-related protein (LRP). Sánchez MC; Chiabrando GA; Vides MA Arch Biochem Biophys; 2001 May; 389(2):218-22. PubMed ID: 11339811 [TBL] [Abstract][Full Text] [Related]
5. Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells. Kuiper J; Otter M; Voorschuur AH; van Zonneveld AJ; Rijken DC; van Berkel TJ Thromb Haemost; 1995 Nov; 74(5):1298-304. PubMed ID: 8607113 [TBL] [Abstract][Full Text] [Related]
6. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop. Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954 [TBL] [Abstract][Full Text] [Related]
7. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541 [TBL] [Abstract][Full Text] [Related]
8. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I). Stoop AA; Jespers L; Lasters I; Eldering E; Pannekoek H J Mol Biol; 2000 Sep; 301(5):1135-47. PubMed ID: 10966811 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library. Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122 [TBL] [Abstract][Full Text] [Related]
10. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis. Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948 [TBL] [Abstract][Full Text] [Related]
11. The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats. van der Kaaden ME; Rijken DC; Kruijt JK; van Berkel TJ; Kuiper J Thromb Haemost; 1997 Apr; 77(4):710-7. PubMed ID: 9134648 [TBL] [Abstract][Full Text] [Related]
12. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries. Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091 [TBL] [Abstract][Full Text] [Related]
13. Native and non-glycosylated recombinant single-chain urokinase-type plasminogen activator are recognized by different receptor systems on rat parenchymal liver cells. van der Kaaden ME; Rijken DC; Groeneveld E; van Berkel TJ; Kuiper J Thromb Haemost; 1995 Aug; 74(2):722-9. PubMed ID: 8585013 [TBL] [Abstract][Full Text] [Related]
14. Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes. Lee JA; Croucher DR; Ranson M Thromb Haemost; 2010 Dec; 104(6):1133-42. PubMed ID: 20838737 [TBL] [Abstract][Full Text] [Related]
15. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor. Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275 [TBL] [Abstract][Full Text] [Related]
16. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein. Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462 [TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator. Sitter T; Toet K; Quax P; Kooistra T Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120 [TBL] [Abstract][Full Text] [Related]
18. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator. van Meijer M; Stoop A; Smilde A; Preissner KT; van Zonneveld AJ; Pannekoek H Thromb Haemost; 1997 Mar; 77(3):516-21. PubMed ID: 9066004 [TBL] [Abstract][Full Text] [Related]
19. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells. Bu G; Maksymovitch EA; Schwartz AL J Biol Chem; 1993 Jun; 268(17):13002-9. PubMed ID: 8389767 [TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility. De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]